Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study.

Abstract

A clinical, retrospective and non-comparative study was undertaken to assess the clinical efficacy and tolerability of azithromycin in the treatment of community-acquired pneumonia caused by Legionella pneumophila. A total of 16 patients with a serologically confirmed diagnosis of Legionnaires' diseases were included. Azithromycin was administered orally at a total dose of 1.5 g for either 3 or 5 days. All patients were no side-effects requiring discontinuation of the treatment. Further increase of abnormal baseline liver function was recorded in 2 patients and in 1 patient mild, transient eosinophilia. Equal clinical efficacy and tolerability were observed with the 3- and 5-day dosage regimen. These results indicate that azithromycin given at a standard dose of 1.5 g is effective and well tolerated in the treatment of Legionnaires' disease.

• Authors: I Kuzman, I Soldo, S Schönwald, J Culig
• Journal: Scandinavian journal of infectious diseases (Scand J Infect Dis) Vol. 27 Issue 5 Pg. 503-5 ( 1995) ISSN: 0036-5548 [Print] England
• PMID: 8588143 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Azithromycin

Topics

• Adult
• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Azithromycin (adverse effects, therapeutic use)
• Community-Acquired Infections (drug therapy)
• Drug Tolerance
• Eosinophilia (chemically induced)
• Humans
• Legionnaires' Disease (drug therapy)
• Liver (drug effects)
• Male
• Middle Aged
• Retrospective Studies